Central Venous Catheters Market

SKU: DMMD78 | Last Updated On: Oct 07 2022 | Available Formats

> Central Venous Catheters Market Expected to reach a high CAGR of 5.4% during the forecast period 2022-2029: DataM Intelligence.

Central Venous Catheters Market is segmented By Property Type (Antimicrobial Coated, Non-antimicrobial coated), By Product Type (Tunneled, Non-tunneled), By Design Type (Single-Lumen, Double-Lumen, Triple-Lumen, Multi-Lumen), By Material Composition Type (Soft, Rigid), By Application (Jugular Vein Cannulation, Subclavian Vein Cannulation, Femoral Vein Cannulation), By End User (Hospitals, Ambulatory Surgical Centers, Specialty clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2022-2029.

 

Central Venous Catheters Market size was valued US$ 1,994.72 million in 2021 and is estimated to reach US$ 3,760.83 million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Central Venous Catheters Market

Metrics

Details

Market CAGR

5.9%

Segments Covered

By Property Type, By Product Type, By Product Type, By Material Composition Type, By Application, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Central venous catheters also known as central lines are primarily used to access the venous system. These catheters are thin, flexible tubes that are placed into the large vein above the heart. These are inserted through the internal jugular vein, femoral vein, and subclavian vein and help in the delivery of intravenous fluids, blood products, medications, parenteral nutrition, and collection of blood samples. It also monitors hemodynamic variables, measures central venous pressure, hemodialysis and chemotherapy.

Central venous catheters need special care like regular cleaning or dressing employing sterile techniques. More than five million central venous catheters are inserted in the U.S. each year. Central venous catheters are used when traditional methods of providing medication are not responding.

Market Dynamics

The central venous catheters market growth is driven by several factors including, the rising incidence of patients with chronic diseases and cancer, increasing adoption of antimicrobial catheters on huge scale in market, novel technological advancements, and various new product launches.

Increasing prevalence of chronic diseases and rising technological advancements are expected to drive the growth of market.

The major drivers fueling the growth of the market are the high prevalence of cancer and chronic diseases, especially in geriatric patients, technical advancements, and the rise in the adoption of antimicrobial catheters on a large scale.

According to National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered in 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO the number of new cases is expected to rise by around 70% by 2030. The administration of chemotherapy drugs is more efficient with the help of central venous catheters, and there is a rise in the adoption of antimicrobial catheters by cancer patients globally.

Even chronic diseases such as renal diseases require catheters, according to the study by the University of California, around 5 million people worldwide are affected by the end-stage renal disease (ESRD), and the number of patients diagnosed with the disease is expected to increase at a rate of 5-7% annually.

Various novel technological advances and latest product launches with latest technologies will contribute towards the growth of central venous catheters. For instance, In Jan 2021, Medtronic announced that DiamondTemp ablation system got approved by United States Food and Drug Administration for treatment of patients that have recurrent, paroxysmal atrial fibrillation.

High cost associated with central venous catheters is expected to hamper the market growth.

Increasing complications such as damage to central veins, pulmonary complications, cardiac complications, device dysfunction, catheter-related bloodstream infection, and rising adoption of other vascular access devices are going to restrain the market in the forecast period, rising adoption of other vascular access devices available in the market and high cost associated with these catheters are few factors that can restrain the growth of central venous catheters market.

According to an article in British Medical Journal, the mean central venous catheter bloodstream infection (CVC-BSI) rate was documented in a large study of 215 UK intensive care units (ICUs) that submitted data for up to 20 months was 2 per 1000 central venous catheter days.

Industry Analysis

The global central venous catheters market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis, and epidemiology.

Segment Analysis

Antimicrobial central venous catheters segment is expected to hold the largest market share in global central venous catheters market

The global central venous catheters market can be segmented by property type as antimicrobial coated and non-antimicrobial coated, by product type as tunneled and non-tunneled, by design type as single-lumen, double-lumen, triple-lumen, and multi-lumen, by material composition type as soft and rigid, by application type as jugular vein cannulation, subclavian vein cannulation, and femoral vein cannulation and by an end-user as hospitals, ambulatory surgical centers, and specialty clinics.

Antimicrobial central venous catheters accounted for more than 30% of the market share. These catheters are impregnated with antimicrobial agents. These can either be an antiseptic surface (silver sulfadiazine/ chlorhexidine) or an antibiotic coating or silver-impregnated collagen cuff. Antimicrobial coated catheters have gained importance in recent years due to an increased focus on the prevention of Healthcare-Associated Infections (HAIs) since the coated devices can provide additional protection against the prevention of bloodstream infections in cases where the device is in prolonged contact with body fluids and tissue.

Soft central venous catheters consist of silicon catheters which accounted for more than 10% of the market. Silicone material catheter is mainly preferred for long-term, tunneled CVCs, as they are soft and flexible. However, these are also used for temporary or short-term purposes. Silicone CVCs exhibit a high coefficient of friction.

Geographical Analysis

North America region holds the largest market share in the global central venous catheters market

As per the research study, the global market is divided into majorly five regions such as North America, South America, Europe, the Middle East, Africa, Asia Pacific, and the Rest of the world.

North America is the leading market for central venous catheters and accounted for a major revenue share of more than 40%. According to the U.S. Department of Health and Human Services, national expenditures for cancer treatment in the U.S. were nearly US$ 125 billion in 2010 and US$ 156 billion by 2020. The reasons are improved medical facilities and greatly developed healthcare infrastructure and rising occurrence of cancer, cardiovascular, end-stage renal diseases, and the growing geriatric population. According to the Centre for Disease Control and Prevention, in 2020, about 150 million intravenous catheters were purchased in the US out of which 5 million were used by oncology patients.

Europe accounts for the second-largest market of central venous catheters. The market is rising because of the increased occurrence of cases of cardiac and cancer-related diseases along with well-developed healthcare infrastructure including advanced machines and equipment. According to WHO, in 2020, about 37% of the population aged over 65 years in Europe had at least one chronic disorder, and 27% of the population from the same age group has two chronic disorders, and 29% of the population has three or more chronic disorders.

Asia Pacific is registering the fastest CAGR due to the increasing number of manufacturers and key market players in this region. Various novel technological advancements and latest product launches are taking place in countries such as India, China, and Japan.

Competitive Landscape

Some of the major key players in the global central venous catheters market are AngioDynamics, B.Braun, Becton Dickinson Company, C.R. Bard, Edwards Lifesciences, Medtronic Plc, Teleflex, Terumo Corporation, and Smiths medical.

The global CVC market is a consolidated market with three companies occupying the majority of the market share. Globally, over 70% of the CVC market is attributed to three major players which are headquartered in the US or Europe. These recognized players include Teleflex, C.R Bard, and B Braun.

Companies are focusing on key strategies such as collaboration, acquisitions, and product launches which are boosting the growth of the market globally. For instance,

  • In Jul 2022, B. Braun Medical Inc. developer of infusion therapy launched its one-time blood control Introcan safety 2 IV catheter. It is developed for safe IV access.
  • In Apr 2022, Terumo announced that Thoraflex hybrid frozen elephant trunk device gor approved by United Stated Food and Drug Administration for commercialising it in U.S. for complex aortic arch disease treatment.
  • In Apr 2022, Franklin Medical Mountain announced it received approval of UltraNav, a transseptal catheter system by United States Food and Drug Administration. It will provide controlled delivery of cardiovascular catheters by transseptal puncture.
  • In Feb 2022, Interrad Medical, a private company of medical devices, and Eloquest Healthcare announced their strategic partnership to expand SecurAcath sales in U.S.
  • In Feb 2022, Medtronic announced U.S. FDA approved Freezor and Freezor Xtra cardiac cryoablation focal catheters. These are the first ablation catheters approved by FDA for the treatment of pediatric atrioventricular nodal reentrant tachycardia.

Global Central Venous Catheters Market – Key Companies to Watch

AngioDynamics:

Overview: AngioDynamics is a transforming medical technology manufacturing company that works for blood-flow restoration in vascular system of the body, increases options for cancer treatment and improved life-quality for the patients. It was founded in 1988 and is headquartered in Latham, New York.

Product Portfolio:

Trio-CT Triple Lumen Acute Hemodialysis Catheter: Trio-CT is a catheter used for central venous access (infusion, hemodialysis and monitoring of central venous pressure) for short period of time. Lumens combination provides access for blood draws, medicine infusion and central venous pressure monitoring.

Key Developments: In Aug 2022, AngioDynamics, company of medical technology announced the clearance received by United States Food and Drugs Administration for Auryon Atherectomy System’s expanded indication to add arterial thrombectomy.

The global central venous catheters market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Peripherally Inserted Central Catheter Market

Central Vascular Access Devices Market

Carbon Fiber Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest